Key result
Scleraxis overexpression drives mesenteric artery stiffness and VSMC proliferation, exacerbated by angiotensin II.
Why the study?
Although scleraxis controls cardiac fibrosis-related gene expression and arterial stiffening is linked to multiple cardiovascular diseases, the vascular role of scleraxis was unknown.
Does scleraxis over-expression alter vascular smooth muscle cell proliferation and mesenteric artery stiffness in mouse models and human aortic smooth muscle cells?
Does scleraxis over-expression alter vascular smooth muscle cell proliferation and mesenteric artery stiffness in mouse models and human aortic smooth muscle cells?
This study provides the first evidence that scleraxis expression in vascular smooth muscle cells regulates arterial stiffness and remodeling in a context-dependent manner influenced by angiotensin II.
Scleraxis modulation of stiffness warrants no clinical action yet; leaves open its role as a therapeutic target in human angiotensin II-driven remodeling.
Background: Arterial stiffness impacts vessel function, and may change due to alterations in wall components such as extracellular matrix (ECM) or vascular smooth muscle cells (VSMC). Stiffening is associated with multiple cardiovascular diseases, thus understanding its regulation is crucial for attenuating vessel pathology and function. We previously showed that scleraxis controls cardiac fibrosis-related gene expression, but its vascular role is unknown. Methods: Using a smooth muscle-specific scleraxis over-expression mouse model and angiotensin II (AngII) minipump infusion, we measured mesenteric artery physical characteristics using pressure myography and assessed vessel structure by histology. We assessed the impact of scleraxis over-expression in human aortic smooth muscle cells (HAOSMC). Results: In vivo scleraxis over-expression stimulated VSMC proliferation and increased mesenteric artery stiffness via a leftward shift of the stress vs strain curve. In vitro, scleraxis over-expression induced HAOSMC proliferation. Scleraxis knockout rightward shifted the mesentery stress vs strain curve. AngII markedly increased scleraxis expression in coronary arteries. Scleraxis over-expression with AngII infusion increased measures of mesentery stiffness, increased VSMC contractility and impaired relaxation, while unexpectedly reducing ECM gene expression and increasing contractile gene expression and media/lumen ratio, suggesting arterial remodeling. Similarly, HAOSMCs infected with scleraxis and treated with AngII demonstrated decreased proliferation, and an increased contractile phenotype. Conclusion: Scleraxis expression in VSMCs is a novel regulator of vascular stiffness via altered proliferation, with its effect varying with AngII presence. These findings reveal the first evidence of a role for scleraxis in vascular structure and function, highlighting its complex and context-dependent impact on vessel characteristics.
No takes yet. Share an insight, caveat, or question.
Al‐Hattab et al. (2026) studied Arterial stiffness. Scleraxis over-expression and angiotensin II infusion vs. Scleraxis knockout / control was evaluated on Mesenteric artery stiffness and vascular smooth muscle cell proliferation and contractility. Scleraxis over-expression increased mesenteric artery stiffness and VSMC proliferation in mice, with angiotensin II co-treatment enhancing contractility and arterial remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: